Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed solid tumor refractory to standard therapy and for which no potentially curative therapy exists, including, but not limited to:
• •* Rhabdomyosarcoma and other soft tissue sarcomas
• •* Ewing's family of tumors
• •* Osteosarcoma
• •* Neuroblastoma
• •* Wilms' tumor
• •* Hepatic tumors
• •* Germ cell tumors
• •* Primary brain tumor
• •Histological confirmation may be waived for brainstem or optic gliomas
• •Measurable or evaluable disease
• •Evidence of progressive disease on prior chemotherapy or radiotherapy or persistent disease after prior surgery
• •PATIENT CHARACTERISTICS:
• •Age:
• •21 and under
• •Performance status:
• •ECOG 0-2
• •Life expectancy:
• •At least 8 weeks
• •Hematopoietic:
• •Absolute granulocyte count greater than 1,500/mm\^3
• •Hemoglobin greater than 8 g/dL
• •Platelet count greater than 100,000/mm\^3
• •Hepatic:
• •Bilirubin normal
• •SGPT less than 2 times upper limit of normal
• •No significant hepatic dysfunction
• •Renal:
• •Creatinine normal OR
• •Creatinine clearance at least 60 mL/min
• •Cardiovascular:
• •No significant cardiac dysfunction
• •Pulmonary:
• •No significant pulmonary dysfunction
• •Other:
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •Able to swallow capsules
• •No significant unrelated systemic illness that would preclude study (e.g., serious infections or organ dysfunction)
• •No prior hypersensitivity to dacarbazine, temozolomide, or polyethylene glycol
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy:
• •At least 1 week since prior colony-stimulating factors (e.g., filgrastim \[G- CSF\], sargramostim \[GM-CSF\], or epoetin alfa)
• •At least 4 months since prior myeloablative therapy requiring bone marrow or stem cell transplantation
• •No concurrent anticancer immunotherapy
• •Chemotherapy:
• •See Disease Characteristics
• •At least 3 weeks since prior chemotherapy (4 weeks for nitrosoureas) and recovered
• •Prior temozolomide allowed provided not administered within past 3 months, no severe toxicities experienced during prior course, and not given in combination with other agents designed to inactivate alanine-glyoxylate aminotransferase
• •No other concurrent investigational or standard anticancer chemotherapy
• •Endocrine therapy:
• •Concurrent corticosteroids for control of brain tumor-associated edema allowed provided on stable or decreasing dose for at least 1 week prior to study
• •Radiotherapy:
• •See Disease Characteristics
• •At least 4 weeks since prior limited-field radiotherapy
• •At least 4 months since prior craniospinal irradiation, total body irradiation, or radiotherapy to more than half of the pelvis
• •Recovered from prior radiotherapy
• •No concurrent anticancer radiotherapy
• •Surgery:
• •See Disease Characteristics
• •Other:
• •At least 4 weeks since other prior investigational therapy and recovered
• •No other concurrent anticancer investigational agents